Exhibit 10.2

STOCK PURCHASE AGREEMENT

BY AND BETWEEN

TARGACEPT, INC.

AND

GLAXO GROUP LIMITED

DATED AS OF JULY 27, 2007

--------------------------------------------------------------------------------

STOCK PURCHASE AGREEMENT

THIS STOCK PURCHASE AGREEMENT (this “Agreement”) is made as of July 27, 2007, by
and between Targacept, Inc., a Delaware corporation (the “Company”), and Glaxo
Group Limited, a company organized under the laws of England (“GSK”).

WHEREAS the Company has agreed to sell, and GSK has agreed to purchase, the
number of shares of the Company’s common stock, $0.001 par value per share
(“Common Stock”), determined pursuant to Section 1.2 (the “Shares”), for an
aggregate purchase price of $15,000,000 (the “Purchase Price”) in accordance
with the terms and provisions hereof.

WHEREAS the Company and GSK are entering into a Product Development and
Commercialization Agreement of even date herewith (the “Product Development and
Commercialization Agreement”).

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency
of which are hereby acknowledged, the parties hereby agree as follows:

SECTION I—PURCHASE AND SALE OF SHARES

1.1. PURCHASE AND SALE OF COMMON STOCK. Subject to the terms and conditions of
this Agreement and in reliance on the representations, warranties and covenants
herein set forth, the Company shall issue and sell to GSK, and GSK shall
purchase from the Company, the Shares for the Purchase Price.

1.2. DETERMINATION OF NUMBER OF SHARES. The number of Shares shall be equal to
the quotient, rounded to the nearest whole number, obtained by dividing
$15,000,000 by 125% of the average of the Daily Volume Weighted Average Prices
of the Common Stock on the NASDAQ Global Market for the sixty (60)-day trading
period ending two (2) trading days prior to the “Effective Date” of the Product
Development and Commercialization Agreement (as defined therein). The Company
represents to GSK that the spreadsheet provided to GSK by the Company on
July 26, 2007 accurately sets forth the Daily Volume Weighted Average Prices for
such period as listed as of such date on www.nasdaq.net.

1.3. CLOSING. Subject to the satisfaction or waiver of the conditions set forth
herein, the purchase of the Shares shall be made at a closing to be held at the
offices of Womble Carlyle Sandridge & Rice, PLLC, One West Fourth Street,
Winston-Salem, North Carolina 27101 (by means of facsimile or overnight mail) on
the date of the Product Development and Commercialization Agreement or such
other date as the Company and GSK may agree, 2007 (the “Closing”).

1.4. CLOSING DELIVERY. At the Closing, subject to the terms and conditions of
this Agreement: (i) GSK shall pay the Purchase Price by wire transfer of
$15,000,000 in immediately available funds in accordance with the wire transfer
instructions previously provided to GSK; (ii) the parties hereto shall enter
into the Product Development and Commercialization Agreement; and (iii) the
Company shall deliver stock certificates representing the Shares. The Shares
shall be registered in the name of GSK.

 

EXECUTION VERSION

--------------------------------------------------------------------------------

1.5. EXEMPTION FROM REGISTRATION. The certificate or certificates for the Shares
(and any securities issued in respect of or exchange for the Shares) shall be
subject to a legend or legends restricting transfer under the Securities Act of
1933, as amended (the “Securities Act”), and referring to restrictions on
transfer herein, such legend to be substantially as follows:

THE SECURITIES REPRESENTED HEREBY HAVE NOT BEEN REGISTERED UNDER THE U.S.
SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR APPLICABLE STATE SECURITIES
LAWS AND NO INTEREST THEREIN MAY BE SOLD, TRANSFERRED OR OTHERWISE DISPOSED OF
UNLESS THERE IS AN EFFECTIVE REGISTRATION STATEMENT FOR SUCH SECURITIES UNDER
THE ACT AND ANY APPLICABLE STATE SECURITIES LAWS OR THE ISSUER OF THESE
SECURITIES RECEIVES AN OPINION OF COUNSEL FOR THE HOLDER OF THESE SECURITIES
SATISFACTORY TO THE ISSUER THAT REGISTRATION IS NOT REQUIRED UNDER THE ACT OR
ANY APPLICABLE STATE SECURITIES LAWS.

THE TRANSFER OF THE SECURITIES REPRESENTED BY THIS CERTIFICATE IS ALSO SUBJECT
TO THE RESTRICTIONS CONTAINED IN THAT CERTAIN STOCK PURCHASE AGREEMENT DATED AS
OF JULY 27, 2007, BY AND BETWEEN TARGACEPT, INC. AND GLAXO GROUP LIMITED.

SECTION II—REPRESENTATIONS AND WARRANTIES OF THE COMPANY

The Company hereby represents, warrants and covenants to GSK, as of the date
hereof, as follows:

2.1. ORGANIZATION AND CORPORATE POWER. The Company is duly organized and validly
existing in good standing under the laws of the jurisdiction of its
organization. The Company has all requisite corporate power and authority to own
its properties and to carry on its business as presently conducted and as
described in its Annual Report on Form 10-K for the year ended December 31,
2006. The Company is qualified to do business as a foreign corporation in each
jurisdiction wherein the character of its property, or the nature of the
activities presently conducted by it, makes such qualification necessary, except
where the failure to be so licensed or qualified would not have a Material
Adverse Effect (as defined below). “Material Adverse Effect” shall mean any
events, occurrences or circumstances which give rise to or would reasonably be
expected to give rise to, individually or in the aggregate, a material adverse
effect on the assets, liabilities, condition (financial or other), business,
results of operations of the Company.

2.2. NO SUBSIDIARIES. The Company does not currently own or control, directly or
indirectly, any interest in any other corporation, partnership, trust, joint
venture, limited liability company, association or other business entity.

2.3. AUTHORIZATION AND NON-CONTRAVENTION. This Agreement is a valid and binding
obligation of the Company, enforceable against the Company in accordance with
its terms, except as enforceability may be limited by applicable bankruptcy,
insolvency, reorganization, moratorium or similar laws affecting creditors’ and
contracting parties’ rights generally and except

 

EXECUTION VERSION   2  

--------------------------------------------------------------------------------

as enforceability may be subject to general principles of equity (regardless of
whether such enforceability is considered in a proceeding in equity or at law).
The execution, delivery and performance of this Agreement, and the sale and
delivery of the Shares in accordance with this Agreement, have been duly
authorized by all necessary corporate or other action of the Company. The
execution, delivery and performance of this Agreement, including, without
limitation, the sale and delivery of the Shares in accordance with this
Agreement and the performance of any transactions contemplated by this Agreement
will not violate, conflict with or result in a default (whether after the giving
of notice, lapse of time or both) under (i) any bond, debenture, note or any
other evidence of indebtedness in any indenture, mortgage deed of trust or any
other material agreement or instrument which would be reasonably likely to have
a Material Adverse Effect, or to cause the creation of any lien or encumbrance
upon any of the assets of the Company except for those which would not have a
Material Adverse Effect, (ii) any provision of the Company’s charter or bylaws,
or (iii) any provision of any law, regulation or rule, or any order of, or any
restriction imposed by any court or other governmental agency applicable to the
Company, except for those which would not have a Material Adverse Effect.

2.4. APPROVALS. No permit, authorization, consent, approval, or order of or by,
or any, notification of or filing with, any person or entity (governmental or
otherwise) is required in connection with the execution, delivery or performance
of this Agreement (including the issuance and sale of the Shares) by the
Company.

2.5. AUTHORIZED AND OUTSTANDING STOCK. As of March 31, 2007, the authorized
capital stock of the Company consists of 100,000,000 shares of Common Stock, of
which 19,142,142 shares are issued and outstanding, and 5,000,000 shares of
Preferred Stock, none of which is issued and outstanding. The Company has not
issued any capital stock since that date other than pursuant to (i) employee
benefit plans disclosed in the SEC Documents (as defined in Section 2.6), or
(ii) outstanding warrants, options or other securities disclosed in the SEC
Documents. There are no preemptive rights, rights of first refusal, put or call
rights or obligations or anti-dilution rights with respect to the issuance or
sale of the Shares. Except as disclosed in the SEC Documents, there are no
stockholders’ agreements, voting agreements or other similar agreements with
respect to the Common Stock to which the Company is a party.

2.6. SEC DOCUMENTS; FINANCIAL STATEMENTS. Since December 31, 2006, the Company
has filed all documents required to be filed with the United States Securities
and Exchange Commission (the “SEC”) pursuant to the reporting requirements of
the Securities Exchange Act of 1934, as amended (the “Exchange Act”) (such
filings since such date, the “SEC Documents”). As of their respective filing
dates, each of the SEC Documents complied in all material respects with the
requirements of the Exchange Act and the rules and regulations of the SEC
promulgated thereunder applicable to such SEC Document, and no SEC Document when
filed contained any untrue statement of a material fact or omitted to state a
material fact required to be stated therein or necessary in order to make the
statements therein, in light of the circumstances under which they were made,
not misleading. The financial statements of the Company and the related notes
contained in the SEC Documents present fairly, in accordance with generally
accepted accounting principles, the financial position of the Company as of the
dates indicated, and the results of its operations and cash flows for the
periods therein specified except that the unaudited interim financial statements
were or are subject to normal and recurring year-end adjustments. Such financial
statements (including the related notes) have been prepared in compliance in all

 

EXECUTION VERSION   3  

--------------------------------------------------------------------------------

material respects with the published rules and regulations of the SEC and in
accordance with generally accepted accounting principles applied on a consistent
basis throughout the periods therein specified, except (i) as may be disclosed
in the notes to such financial statements, (ii) in the case of unaudited
statements, as may be permitted by the SEC on Form 10-Q under the Exchange Act
and (iii) as disclosed in the SEC Documents.

2.7. NO VIOLATIONS. The Company is not: (i) in violation of its charter, bylaws,
or other organizational document or any law, administrative regulation,
ordinance or order of any court or governmental agency, arbitration panel or
authority applicable to the Company, which violation, individually or in the
aggregate, would be reasonably likely to have a Material Adverse Effect, or
(ii) in default (and there exists no condition which, with the passage of time
or otherwise, would constitute a default) in the performance of any bond,
debenture, note or any other evidence of indebtedness in any indenture,
mortgage, deed of trust or any other material agreement or instrument which is
filed as an exhibit to the SEC Documents and which would be reasonably likely to
have a Material Adverse Effect.

2.8. NASDAQ COMPLIANCE. The Company’s Common Stock is listed on The NASDAQ
Global Market and the Company has taken no action designed to, or likely to have
the effect of, de-listing the Common Stock from The NASDAQ Global Market, nor
has the Company received any notification that the SEC or the National
Association of Securities Dealers, Inc. (the “NASD”) is contemplating
terminating such registration or listing. The Company shall comply in all
material respects with all requirements of the NASD and the SEC with respect to
the issuance of the Shares and the initial listing of the Shares on The NASDAQ
Global Market.

2.9. COMPANY NOT AN “INVESTMENT COMPANY.” The Company has been advised generally
of the rules and requirements under the Investment Company Act of 1940, as
amended (the “Investment Company Act”). To the knowledge of the Company, the
Company is not, and immediately after receipt of payment for the Shares will not
be, an “investment company” or an entity “controlled” by an “investment company”
within the meaning of the Investment Company Act.

2.10. PRIVATE OFFERING. Assuming the correctness of the representations and
warranties of GSK set forth in Section 3 hereof, the offer and sale of the
Shares hereunder is exempt from registration under the Securities Act.

2.11. NO BROKERS OR FINDERS. No person has or will have, as a result of the
transactions contemplated by this Agreement, any right, interest or claim
against or upon the Company for any commission, fee or other compensation as a
finder or broker because of any act or omission by the Company or its
stockholders or its affiliates.

2.12. VALID ISSUANCE OF SHARES. When issued, sold and delivered in accordance
with the terms hereof for the consideration provided herein, the Shares shall be
duly authorized, validly issued, fully paid and nonassessable, free from any
encumbrances or restrictions on transfer other than restrictions on transfer
under this Agreement and under federal and state securities laws.

 

EXECUTION VERSION   4  

--------------------------------------------------------------------------------

SECTION III—REPRESENTATIONS AND WARRANTIES OF GSK

GSK hereby represents, warrants and covenants to the Company, as of the date
hereof, as follows:

3.1. INVESTMENT REPRESENTATIONS. (i) (A) GSK is an “accredited investor” as
defined in Regulation D under the Securities Act and is knowledgeable,
sophisticated, able to fend for itself and experienced in making, and is
qualified to make decisions with respect to investments in shares presenting an
investment decision like that involved in the purchase of the Shares, including
investments in securities issued by the Company and investments in comparable
companies, and has requested, received, reviewed and considered all information
it deemed relevant in making an informed decision to purchase the Shares and
(B) the Company has made available to GSK, prior to the date hereof, the
opportunity to ask questions of and receive complete and correct answers from
representatives of the Company concerning the terms and conditions of the Shares
and to obtain any additional information relating to the financial condition and
business of the Company and GSK has such knowledge and experience in financial
and business matters that GSK is capable of evaluating the merits and risks of
the investment in the Shares; (ii) GSK is acquiring the Shares for its own
account for investment only and with no present intention of distributing any of
the Shares or any arrangement or understanding with any other persons regarding
the distribution of the Shares; (iii) GSK will not, directly or indirectly,
offer, sell, pledge, transfer or otherwise dispose of (or solicit any offers to
buy, purchase or otherwise acquire or take a pledge of) any of the Shares except
in compliance with Section 4.2 of this Agreement, the Securities Act, applicable
state securities laws and the respective rules and regulations promulgated
thereunder, and acknowledges that certificates evidencing the Shares will be
imprinted with a legend that prohibits their transfer except in accordance
therewith; and (iv) GSK has, in connection with its decision to purchase the
Shares relied only upon the SEC Documents and the representations and warranties
of the Company contained herein. GSK understands that its acquisition of the
Shares has not been registered under the Securities Act or registered or
qualified under any state securities law in reliance on specific exemptions
therefrom, which exemptions may depend upon, among other things, the bona fide
nature of GSK’s investment intent as expressed herein.

3.2. COMPLIANCE WITH FOREIGN SECURITIES LAWS. To the knowledge of GSK, no action
is required to be taken in any jurisdiction outside the United States by the
Company to permit an offering of the Shares to GSK or the possession by or
distribution of offering materials to GSK in connection with the issue of the
Shares. GSK will comply with all applicable laws and regulations in each foreign
jurisdiction in which it purchases, offers, sells or delivers the Shares, or has
in its possession or distributes any offering material, in all cases at its own
expense.

3.3. AUTHORITY. (i) GSK is duly organized and validly existing under the laws of
the country under which it was organized and has full corporate or other power
and authority under its governing instruments and such laws to conduct its
business as now conducted and to execute, deliver and perform this Agreement,
(ii) GSK has full right, power, authority and capacity to enter into this
Agreement and to consummate the transactions contemplated hereby and has taken
all necessary action to authorize the execution, delivery and performance of
this Agreement, and (iii) this Agreement constitutes a valid and binding
obligation of GSK enforceable

 

EXECUTION VERSION   5  

--------------------------------------------------------------------------------

against GSK in accordance with its terms, except as enforceability may be
limited by applicable bankruptcy, insolvency, reorganization, moratorium or
similar laws affecting creditors’ and contracting parties’ rights generally and
except as enforceability may be subject to general principles of equity
(regardless of whether such enforceability is considered in a proceeding in
equity or at law).

3.4. INVESTMENT BANKING; BROKERAGE FEES. GSK has not incurred or taken any
action so that the Company is or may become liable for any investment banking
fees, brokerage commissions, broker’s or finder’s fees or similar compensation
in connection with the transactions contemplated by this Agreement.

SECTION IV—COVENANTS OF THE PARTIES

4.1. RULE 144. The Company covenants that it will use commercially reasonable
efforts to timely file the reports required to be filed by it under the Exchange
Act and the rules and regulations adopted by the SEC thereunder (or, if the
Company is not required to file such reports, it will, upon the request of GSK
(or any of its affiliates which then holds any of the Shares) made after the
first anniversary of the Closing, make publicly available such information as
necessary to permit sales pursuant to Rule 144 under the Securities Act), and it
will take such further action as GSK may reasonably request, all to the extent
required from time to time to enable GSK, whichever then holds any of the
Shares, to sell such Shares without registration under the Securities Act but
within the limitations of Rule 144 under the Securities Act, as such Rule may be
amended from time to time, or any successor rule or regulation hereafter adopted
by the SEC (but subject, in any case, to applicable insider trading laws). Upon
the reasonable request of GSK, the Company will deliver to such holder a written
statement as to whether it has complied with such and requirements.

4.2. SELLING RESTRICTIONS.

A. Except as set forth in this Section 4.2(A), GSK agrees that it shall not
sell, transfer, pledge, hypothecate or otherwise dispose of (each a “Transfer”)
any of the Shares purchased at the Closing prior to the first anniversary of the
Closing and, thereafter only in compliance with Rule 144 or other applicable
exemption from registration under the Securities Act. The restriction on
Transfer set forth in this Section 4.2 shall not apply to Transfers to a
subsidiary or parent of GSK or to “affiliates” (as defined in Rule 405 of the
Securities Act) or stockholders of GSK, provided that each transferee agrees in
writing as a condition precedent to such Transfer to be bound by the terms of
this Agreement. For as long as GSK and its affiliates together own more than
five percent (5%) of the outstanding shares of Common Stock, GSK shall give the
Company written notice of any intended Transfer of any of the Shares not later
than the time of such Transfer. GSK also agrees and consents to the entry of
stop transfer instructions with the Company’s transfer agent and registrar to
restrict the transfer of the Shares except in compliance with this Section 4.2.

B. GSK agrees that it shall not, and it shall cause its affiliates not to,
directly or indirectly, sell any shares of Common Stock that it (or its
affiliate) does not “own” (within the meaning of Rule 200(b) and (c) of
Regulation SHO promulgated by the SEC under the Exchange Act). Without limiting
the generality of the foregoing, GSK shall not, and shall cause its affiliates
not

 

EXECUTION VERSION   6  

--------------------------------------------------------------------------------

to, (i) enter into a short position with respect to any shares of Common Stock,
(ii) grant any option to purchase or acquire any right to dispose or otherwise
dispose for value of any shares of Common Stock or any securities convertible
into, exercisable for or exchangeable for any shares of Common Stock, or
(iii) enter into any swap, hedge or other agreement that transfers, in whole or
in part, the economic risk of ownership of any shares of Common Stock.

4.3. CONFIDENTIALITY; NON-DISCLOSURE. Each party represents to the other that,
at all times during the Company’s offering of the Shares to GSK, it has
maintained in confidence all non-public information regarding the other, and
covenants that it will continue to maintain in confidence such information until
such information pursuant to Article 9 of the Product Development and
Commercialization Agreement, except as follows: (i) at Closing, the Company may
issue a press release disclosing information regarding its transaction with GSK
that the Company believes constitutes material and non-public information and
(ii) the Company shall, within four (4) business days of the Closing, file with
the SEC a report on Form 8-K disclosing the material terms of the transactions
contemplated hereby and by the Product Development and Commercialization
Agreement. For the avoidance of doubt, the parties agree that the information to
be disclosed by the Company hereunder shall be deemed authorized disclosure
under Section 9.2 of the Product Development and Commercialization Agreement.

SECTION V—MISCELLANEOUS

5.1. SURVIVAL OF REPRESENTATIONS AND WARRANTIES. The representations and
warranties of the Company and GSK contained herein shall survive the execution
of this Agreement, the delivery to GSK of the Shares being purchased and the
payment therefor until 12 months from and after the date hereof.

5.2. AMENDMENTS, WAIVERS AND CONSENTS. For the purposes of this Agreement,
except as otherwise specifically set forth herein, no course of dealing between
the Company on the one hand and GSK on the other and no delay on the part of any
party hereto in exercising any rights hereunder or thereunder shall operate as a
waiver of the rights hereof and thereof. Any term or provision hereof may be
amended, terminated or waived (either generally or in a particular instance and
either retroactively or prospectively) only with the written consent of the
Company and GSK.

5.3. NOTICES AND DEMANDS. All notices, requests, demands and other
communications hereunder shall be in writing and shall be deemed to have been
duly given if faxed (with transmission acknowledgment received), delivered
personally or mailed by certified or registered mail (return receipt requested)
as follows:

 

EXECUTION VERSION   7  

--------------------------------------------------------------------------------

To the Company:  

Targacept, Inc.

200 East First Street, Suite 300

Winston-Salem, NC 27101

Attention: Chief Executive Officer

Attention: General Counsel

Facsimile: (336) 480-2103

With a copy to:  

Womble Carlyle Sandridge & Rice, PLLC

One West Fourth Street

Winston-Salem, NC 27101

Attention: Jeffrey C. Howland

Facsimile: (336) 733-8371

 

To GSK:

Glaxo Group Limited

GSK House

980 Great West Road,

Brentford, Middlesex

TW8 9GS

United Kingdom

 

Attn: Corporate Secretariat

Facsimile: 44 20 8047 6904

 

With a copies to:

GlaxoSmithKline

2301 Renaissance Blvd.

Mail Stop (RNO220)

King of Prussia, PA 19101

 

Attn: Vice President &

Associate General Counsel

Facsimile: 610-787-7084

  and  

GlaxoSmithKline

One Franklin Plaza (FP2355)

200 N. 16th Street

Philadelphia, PA 19102

 

Attn: VP & Associate General

Counsel, Corporate Functions - US

Facsimile: (215) 751-5349

or to such other address or fax number of which any party may notify the other
parties as provided above. Notices shall be effective as of the date of such
delivery, mailing or fax.

5.4. SEVERABILITY. Whenever possible, each provision of this Agreement shall be
interpreted in such a manner as to be effective and valid under applicable law,
but if any provision of this Agreement shall be deemed prohibited or invalid
under such applicable law, such provision shall be ineffective to the extent of
such prohibition or invalidity, and such prohibition or invalidity shall not
invalidate the remainder of such provision or the other provisions of this
Agreement.

5.5. EXPENSES. Each of the parties shall be responsible for its own costs and
expenses incurred in connection with the transactions contemplated hereby and
all agreements, documents and instruments executed pursuant hereto.

 

EXECUTION VERSION   8  

--------------------------------------------------------------------------------

5.6. COUNTERPARTS. This Agreement may be executed in multiple counterparts, each
of which shall constitute an original but all of which shall constitute but one
and the same instrument. One or more counterparts of this Agreement may be
delivered via telecopier, with the intention that they shall have the same
effect as an original counterpart hereof.

5.7. EFFECT OF HEADINGS; CONSTRUCTION. The descriptive headings in this
Agreement have been inserted for convenience only and shall not be deemed to
limit or otherwise affect the construction of any provision thereof or hereof.
The parties have participated jointly in the negotiation and drafting of this
Agreement with counsel sophisticated in investment transactions. In the event an
ambiguity or question of intent or interpretation arises, this Agreement and the
agreements, documents and instruments executed and delivered in connection
herewith shall be construed as if drafted jointly by the parties and no
presumption or burden of proof shall arise favoring or disfavoring any party by
virtue of the authorship of any provisions of this Agreement and the agreements,
documents and instruments executed and delivered in connection herewith.

5.8. GOVERNING LAW. This Agreement shall be deemed a contract made under the
laws of North Carolina and all disputes, claims or controversies arising out of
this Agreement, or the negotiation, validity or performance hereof or the
transactions contemplated herein, shall be construed under and governed by the
laws of such state, without giving effect to its conflicts of laws principles.

5.9. ENTIRE AGREEMENT. This Agreement (and the provisions of the Product
Development and Commercialization Agreement specifically referenced herein)
constitutes the full and entire understanding and agreement among the parties
hereto with respect to the subject matters hereof and thereof, and any and all
other written or oral agreements existing prior to or contemporaneously herewith
are expressly superseded and canceled.

[SIGNATURE PAGE FOLLOWS]

 

EXECUTION VERSION   9  

--------------------------------------------------------------------------------

IN WITNESS WHEREOF, the undersigned have executed this Stock Purchase Agreement
as of the day and year first above written.

 

COMPANY: TARGACEPT, INC. By:  

/s/ J. Donald deBethizy

Name:   J. Donald deBethizy Title:   President and CEO GSK: GLAXO GROUP LIMITED
By:  

/s/ Paul Williamson

Name:   Paul Williamson Title:   For and on behalf of   Edinburgh Pharmaceutical
Industries Limited   Corporate Director